Monday November 23 2009 | Biotechnology feed | All feeds

Cell Therapeutics, Inc.

Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma

BioPortfolio no longer holds the full text of this article, it is however likley to be available via the below links:

Three Italian Multicenter Studies Report High (>70%) Rates of ... 9 Dec 2008 ... Cell Therapeutics, Inc. announced today that the results of three Italian multicenter studies utilizing Zevalin(R) ( 90Y -ibritumomab ...
http://www.drugs.com/clinical_trials/three-italian-multicent...
Three Italian Multicenter Studies Report High (>70%) Rates of ... Three Italian Multicenter Studies Report High (70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly ...
http://www.reuters.com/article/pressRelease/idUS60185+09-Dec...
Archive News & Video for Tuesday, 09 Dec, 2008 | Reuters.com Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission ... 01:30 AM EST. Delta, Northwest Pilots Get Seniority Ruling 01:24 AM EST ...
http://www.reuters.com/resources/archive/us/20081209.html...

Browse other news from this organisation: Cell Therapeutics, Inc.

(If any, Generated Automatically)

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.